Patents by Inventor Michael Famulok

Michael Famulok has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200123547
    Abstract: The present invention relates to a nucleic acid-based assembly comprising: at least one nucleic acid aptamer, and at least one nucleic acid motif designed to physically capture a drug. The nucleic acid motif may comprise one or more photo-responsive moieties that effect the release of the drug upon irradiation. The aptamer and the nucleic acid motif each can be covalently linked to one or more lipids, and the lipid-modified aptamer and nucleic acid motif may form the assembly through noncovalent interaction. The invention further relates to use of the nucleic acid-based assembly in the treatment of cancer.
    Type: Application
    Filed: December 7, 2017
    Publication date: April 23, 2020
    Applicant: Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Michael FAMULOK, Deepak PRUSTY, Adam VOLKER, Stephan IRSEN
  • Patent number: 10551388
    Abstract: The present invention relates to a method of determining a protein in a sample and the use of the method for the identification of aptamer target proteins.
    Type: Grant
    Filed: January 15, 2018
    Date of Patent: February 4, 2020
    Assignee: Rheinische Friedrich-Wilhelms-Universitat Bonn
    Inventors: Michael Famulok, Gunter Mayer, Jan Vinkenborg
  • Publication number: 20180143201
    Abstract: The present invention relates to a method of determining a protein in a sample and the use of the method for the identification of aptamer target proteins.
    Type: Application
    Filed: January 15, 2018
    Publication date: May 24, 2018
    Inventors: Michael FAMULOK, Gunter MAYER, Jan VINKENBORG
  • Patent number: 9939443
    Abstract: Methods are provided for selecting aptamers that are specific to a target of interest from amongst a library of potential aptamer sequences. Aptamers disclosed can be used to detect and/or characterize biological entities of interest, e.g. microvesicles and/or surface antigens. Further disclosed are biomarkers that can be used for diagnosing different disorders including different types of cancer.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: April 10, 2018
    Assignee: Caris Life Sciences Switzerland Holdings GmbH
    Inventors: David Spetzler, Valeriy Domenyuk, Tassilo Hornung, Günter Mayer, Michael Famulok
  • Patent number: 9910045
    Abstract: The present invention relates to a method of determining a protein in a sample and the use of the method for the identification of aptamer target proteins.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: March 6, 2018
    Assignee: RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITAT BONN
    Inventors: Michael Famulok, Gunter Mayer, Jan Vinkenborg
  • Publication number: 20170059576
    Abstract: The present invention relates to a method of determining a protein in a sample and the use of the method for the identification of aptamer target proteins.
    Type: Application
    Filed: September 7, 2016
    Publication date: March 2, 2017
    Inventors: Michael FAMULOK, Gunter MAYER, Jan VINKENBORG
  • Publication number: 20160069889
    Abstract: Methods are provided for selecting aptamers that are specific to a target of interest from amongst a library of potential aptamer sequences. Aptamers disclosed can be used to detect and/or characterize biological entities of interest, e.g. microvesicles and/or surface antigens. Further disclosed are biomarkers that can be used for diagnosing different disorders including different types of cancer.
    Type: Application
    Filed: December 19, 2013
    Publication date: March 10, 2016
    Inventors: David SPETZLER, Valeriy DOMENYUK, Tassilo HORNUNG, Günter MAYER, Michael FAMULOK
  • Publication number: 20150204878
    Abstract: The present invention relates to a method of determining a protein in a sample and the use of the method for the identification of aptamer target proteins.
    Type: Application
    Filed: July 25, 2013
    Publication date: July 23, 2015
    Inventors: Michael Famulok, Gunter Mayer, Jan Vinkenborg
  • Publication number: 20130245275
    Abstract: The present invention relates to phenyl diamides according to the general formula (1) and their use as a medicament and a pharmaceutical preparation comprising as an active ingredient a phenyl diamide according to the general formula (1). Further, the present invention relates to phenyl diamides according to the formulas (16), (17) and (18) for use in the treatment of gliomas.
    Type: Application
    Filed: October 4, 2011
    Publication date: September 19, 2013
    Applicant: Rheinische Friedrich-Wilhelms Universitaet Bonn
    Inventors: Michael Famulok, Anke Bill, Anton Schmitz, Juergen Bajorath
  • Patent number: 8163788
    Abstract: The invention relates to a pharmaceutical composition and the use thereof, wherein the pharmaceutical composition contains compounds selected from a group of general formulas (5), (6), (7) and (8) and/or enantiomers, diastereomers or the pharmaceutically acceptable salts thereof. The pharmaceutical composition is used for treating autoimmune and tumoral diseases and/or for immunosuppresion.
    Type: Grant
    Filed: November 18, 2005
    Date of Patent: April 24, 2012
    Assignee: Rheinische Friedrich-Wilhelms Universitat Bonn
    Inventors: Michael Famulok, Waldemar Kolanus, Markus Hafner, Imke Grune, Barbara Tappertzhofen, Mirko Theis
  • Publication number: 20100048594
    Abstract: The invention relates to compounds selected from among the group comprising general formulas (1), (2), (3), and/or (4) and/or the enantiomers, diastereomers, and derivatives thereof, and the pharmaceutically acceptable salts thereof for producing a medicament used for therapeutically and/or preventively treating disease and pathological conditions linked to regulation of the insulin and/or insulin-like growth factor (IGF) signalling pathway and/or for chemically inducing longevity.
    Type: Application
    Filed: November 14, 2007
    Publication date: February 25, 2010
    Applicant: RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITAT
    Inventors: Michael Famulok, Markus Hafner, Anton Schmitz, Bernhard Fuss, Ingo Zinke, Michael Hoch
  • Publication number: 20090105286
    Abstract: The invention relates to drugs and the use thereof, wherein said drugs contain compounds selected from a group comprising general formulas (1), (2), (3) and (4) and/or enantiomers, diastereomers or the pharmaceutically acceptable salts thereof. Said drugs are used for treating autoimmune and tumoral diseases and/or for immunosuppresion.
    Type: Application
    Filed: November 18, 2005
    Publication date: April 23, 2009
    Applicant: Rheinische Friedrich-Wilhelms Universitat
    Inventors: Michael Famulok, Waldemar Kolanus, Markus Hafner, Imke Grune, Barbara Tappertzhofen, Mirko Theis
  • Publication number: 20070287153
    Abstract: Described are methods for the identification and validation of (1) functional intracellular targets and (2) nucleic acids (intramers) which are capable of binding to and modifying the function of said intracellular targets. These nucleic acids or, alternatively, compounds showing the same or a similar target specificity and/or effect are useful for the preparation of therapeutics, particularly for gene therapy.
    Type: Application
    Filed: May 25, 2006
    Publication date: December 13, 2007
    Inventors: Michael Blind, Michael Famulok, Waldemar Kolanus
  • Publication number: 20050202423
    Abstract: Disclosed is a method for identifying compounds (lead structures) which specifically bind to (a) desired RNA target motif and can inhibit or eliminate the function thereof or (b) suppress a compound associated with a desired RNA target motif and can thereby inhibit or eliminate the function thereof. The inventive method is based on the attachment of a ligand (=a compound to be identified) to a RNA target motif which is coupled to a modified ribozyme so that the ribozyme is transformed into an active or inactive conformation resulting in the cleaving of a signal-giving ribozyme substrate. The identified compounds enabling modification of the cellular function of the RNA target motifs enable specific medicaments to be produced. The invention also relates to a polynucleotide comprising a hammerhead ribozyme and an aptamer for a target molecule.
    Type: Application
    Filed: November 21, 2001
    Publication date: September 15, 2005
    Inventors: Andres Jenne, Michael Blind, Michael Famulok, Seyed Najafi-Shoushtari, Jorg Hartig
  • Patent number: 6861223
    Abstract: Compositions (reporter systems), which contain a ribozyme-encoding DNA sequence and an oligonucleotide substrate that is cleaved by the ribozyme transcribed by the DNA sequence, are described. In a preferred embodiment, the oligonucleotide substrate is labeled by a fluorophore group (reporter group) and a fluorescence-quenching group (quencher group), the fluorescence of the fluorophore being prevented from being quenched by the fluorescence-quenching group after cleavage by the ribozyme has taken place, and therefore a fluorescence signal is generated. Moreover, methods for measuring transcription rates, for instance for determining transcription-inhibitors or transcription activators, are described.
    Type: Grant
    Filed: August 8, 2002
    Date of Patent: March 1, 2005
    Inventors: Andreas Jenne, Michael Famulok
  • Publication number: 20040170990
    Abstract: The invention relates to a nucleic acid, especially an isolated nucleic acid, that is capable of binding to a guanine nucleotide exchange factor for ADP ribosylation factors, and to the derivatives thereof.
    Type: Application
    Filed: April 1, 2004
    Publication date: September 2, 2004
    Inventors: Kolanus Waldemar, Michael Famulok, Michael Blind, Gunter Mayer
  • Publication number: 20030119019
    Abstract: The invention describes a process for the identification and isolation of nucleic acid molecules capable of distinguishing the isoforms PrPc and PrPSc of prion proteins as well as nucleic acid molecules obtainable by this process. Furthermore, pharmaceutical compositions and diagnostic compositions are described which comprise nucleic acid molecules specifically binding prion protein isoforms as well as diagnostic methods using such molecules.
    Type: Application
    Filed: July 3, 2002
    Publication date: June 26, 2003
    Inventors: Ernst-Ludwig Winnacker, Stefan Weiss, Michael Famulok
  • Publication number: 20030008315
    Abstract: Compositions (reporter systems), which contain a ribozyme-encoding DNA sequence and an oligonucleotide substrate that is cleaved by the ribozyme transcribed by the DNA sequence, are described. In a preferred embodiment, the oligonucleotide substrate is labeled by a fluorophore group (reporter group) and a fluorescence-quenching group (quencher group), the fluorescence of the fluorophore being prevented from being quenched by the fluorescence-quenching group after cleavage by the ribozyme has taken place, and therefore a fluorescence signal is generated. Moreover, methods for measuring transcription rates, for instance for determining transcription-inhibitors or transcription activators, are described.
    Type: Application
    Filed: August 8, 2002
    Publication date: January 9, 2003
    Inventors: Andreas Jenne, Michael Famulok
  • Patent number: 6451535
    Abstract: Compositions (reporter systems), which contain a ribozyme-encoding DNA sequence and an oligonucleotide substrate that is cleaved by the ribozyme transcribed by the DNA sequence, are described. In a preferred embodiment, the oligonucleotide substrate is labeled by a fluorophore group (reporter group) and a fluorescence-quenching group (quencher group), the fluorescence of the fluorophore being prevented from being quenched by the fluorescence-quenching group after cleavage by the ribozyme has taken place, and therefore a fluorescence signal is generated. Moreover, methods for measuring transcription rates, for instance for determining transcription-inhibitors or transcription activators, are described.
    Type: Grant
    Filed: November 20, 2000
    Date of Patent: September 17, 2002
    Inventors: Andreas Jenne, Michael Famulok
  • Patent number: 6426409
    Abstract: The invention describes a process for the identification and isolation of nucleic acid molecules capable of distinguishing the isoforms PrPc and PrPSc of prion proteins as well as nucleic acid molecules obtainable by this process. Furthermore, pharmaceutical compositions and diagnostic compositions are described which comprise nucleic acid molecules specifically binding prion protein isoforms as well as diagnostic methods using such molecules.
    Type: Grant
    Filed: October 2, 1998
    Date of Patent: July 30, 2002
    Inventors: Ernst-Ludwig Winnacker, Stefan Weiss, Michael Famulok